We herein showed that the ex vivo treatment of JAK2V617F MPN primary cells with the IRS/IGF1R inhibitor NT157 resulted in reduced cell viability and had cumulative effects with ruxolitinib. The gene discussed is IGF1R; the disease is myeloproliferative neoplasm.